Using ctDNA to help inform the management of patients with low-risk colorectal cancer

Using ctDNA to help inform the management of patients with locally advanced rectal cancer (with subtitles)

Using ctDNA to help inform the management of patients with locally advanced rectal cancer

The expanding role of ctDNA in colorectal cancer to optimize patient management

The expanding role of ctDNA in colorectal cancer to optimize patient management (with subtitles)

How ctDNA can transform interventional trial design for GI cancers

Seeing the Forest Through the Trees: How tumor informed MRD testing can illuminate the treatment pathway in GI cancer

Review recently presented MRD data in colorectal and pancreatic cancer, exploring the potential impact on patient care

Seeing the Forest Through the Trees: Using tumor-informed MRD testing to illuminate the treatment pathway in GI cancer

Personalized ctDNA testing to help guide treatment decisions in breast cancer

Webinar: Breast Cancer 2023 Data & Post-SABCS Summary

ctDNA in drug development for breast cancer Multiple studies have demonstrated that detection of molecular residual disease (MRD) is associated with poor prognosis in breast cancer. Ongoing prospectiv

Panel Discussion: How ctDNA Testing is Informing the Management of Patients With GI Cancer - Direct

Our experts will review real-world case studies showing when and where ctDNA can help inform shared decision-making.

Locate and Track: ctDNA Monitoring in NSCLC with Signatera

Learn about the clinical applications for Signatera in NSCLC across early stage and metastatic disease

Keith's Story

Listen in how one CRC patient and his physician used Signatera as a part of his treatment strategy to help identify an early signal that cancer may be lurking.

ctDNA monitoring to optimize immunotherapy treatment decisions

Dive into the latest data highlighting ctDNA for immunotherapy treatment response monitoring

Detect. Monitor. Optimize: Signatera’s Impact on Breast Cancer Management

Learn more about the latest Signatera™ data in high-risk breast cancer: Newly published data from the I-SPY 2 trial reinforcing the utility of ctDNA monitoring during neoadjuvant therapy Updates from

Signatera Ordering

Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development

Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for

Powering Precision: The essential role of ctDNA testing for MRD assessment in GI malignancies - Direct

In this webinar, we explore how ctDNA can help bring clarity to common clinical scenarios including adjuvant treatment decision making, indeterminate findings and assessing treatment response.

3988 - Natera - Tampa - Breast Cancer V6e (1)